Evidence map›Paper›PMID 42356022›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.

Ali Fuat Gürbüz, Mehmet Zahid Koçak, Oğuzhan Yıldız, Ömer Genç, Bahattin Engin Kaya, Talat Aykut, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali Fuat GürbüzDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0003-1455-471X
Mehmet Zahid KoçakDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0003-3085-7964
Oğuzhan YıldızDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0002-4057-3108
Ömer GençDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0002-4252-1029
Bahattin Engin KayaDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0002-3414-5596
Talat AykutDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0002-9614-0651
Melek Karakurt EryılmazDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.
Murat ArazDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0002-4632-9501
Mehmet ArtaçDepartment of Medical Oncology, Necmettin Erbakan University, Konya 42080, Turkey.ORCID 0000-0003-2335-3354

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellC-Reactive ProteinKidney NeoplasmsLymphocytesNivolumabAgedBiomarkersFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsRetrospective StudiesROC CurveBiomarkersC-Reactive ProteinNivolumabCALLY indeximmunotherapynivolumabprognostic biomarkerrenal cell carcinoma

Identifiers

PMID42356022
PMCPMC13302872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.